TY - CHAP M1 - Book, Section TI - Myelodysplastic Syndromes A1 - Attar, Eyal C. A2 - Chabner, Bruce A. A2 - Longo, Dan L. PY - 2016 T2 - Harrison's Manual of Oncology, 2e AB - Myelodysplastic syndromes (MDS) represent premalignant entities that share many characteristics with acute myeloid leukemia (AML). These clonal hematopoietic stem cell (HSC) disorders are characterized by pancytopenia resulting from failure of normal hematopoiesis. The bone marrow shows hypercellularity, arrested maturation in one or more cellular lineages, and an increase in bone marrow myeloid precursors. Clinical symptoms result from cytopenias. Approximately one-third of patients ultimately progress to AML. Treatment involves supportive care and the use of agents capable of ameliorating cytopenias and delaying development of AML. However, hematopoietic stem cell transplantation (HCT) represents the only potentially curative treatment for MDS. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/07 UR - hemonc.mhmedical.com/content.aspx?aid=1127647715 ER -